Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists
Open Access
- 26 September 2011
- journal article
- research article
- Published by Springer Nature in BMC Biotechnology
- Vol. 11 (1) , 88
Abstract
Background: Unmethylated cytosine-guanine (CpG) motif-containing oligodeoxynucleotides (ODNs) have been well characterized as agonists of Toll-like receptor 9 (TLR9). ODNs with a phosphorothioate (PTO) backbone have been studied as TLR9 agonists since natural ODNs with a phosphodiester (PD) backbone are easily degraded by a serum nuclease, which makes them problematic for therapeutic applications. However, ODNs with a PTO backbone have been shown to have undesirable side effects. Thus, our goal was to develop nuclease-resistant, PD ODNs that are effective as human TLR9 (hTLR9) agonists.Results: The sequence of ODN2006, a CpG ODN that acts as an hTLR9 agonist, was used as the basic CpG ODN material. The 3'-end modification of ODN2006 with a PD backbone (PD-ODN2006) improved its potential as an hTLR9 agonist because of increased resistance to nucleolytic degradation. Moreover, 3'-end modification with oligonucleotides showed higher induction than modification with biotin, FITC, and amino groups. Further, enhancement of hTLR9 activity was found to be dependent on the number of CpG core motifs (GTCGTT) in the PD ODN containing the 3'-end oligonucleotides. In particular, ODN sequences consisting of two to three linked ODN2006 sequences with a PD backbone (e.g., PD-ODN2006-2006 and PD-ODN2006-2006-2006) acted as effective agonists of hTLR9 even at lower concentrations.Conclusions: This study showed that PD-ODN2006-2006 and PD-ODN-2006-2006-2006 can be used as potentially safe agonists for hTLR9 activation instead of CpG ODNs with a PTO backbone. We propose these CpG ODNs consisting of only a PD backbone as a novel class of CpG ODN.Keywords
This publication has 31 references indexed in Scilit:
- A Novel Class of Immune-Stimulatory CpG Oligodeoxynucleotides Unifies High Potency in Type I Interferon Induction with Preferred Structural PropertiesOligonucleotides, 2010
- Peptide Conjugation at the 5′-End of Oligodeoxynucleotides Abrogates Toll-Like Receptor 9-Mediated Immune Stimulatory ActivityBioconjugate Chemistry, 2009
- Use of CpG oligonucleotides in treatment of asthma and allergic diseaseAdvanced Drug Delivery Reviews, 2009
- CpG oligonucleotides as adjuvants for vaccines targeting infectious diseasesAdvanced Drug Delivery Reviews, 2009
- Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotidesJournal of Controlled Release, 2004
- Rational design of new CpG oligonucleotides that combine B cell activation with high IFN‐α induction in plasmacytoid dendritic cellsEuropean Journal of Immunology, 2003
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002
- Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cellsEuropean Journal of Immunology, 2001
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted PolyamideScience, 1991